Obermatt

Siegfried

SWX:SFZN · CH1429326825
Life Sciences Tools & ServicesMedium

360

63
EV / EBIT67
Price / Owner Earnings8
Owner Earnings Yield49
Dividend Yield55
Price/Sales58
EV / Gross Profit38
Price/Book51
Return on Capital79
Cash Return on Capital49
Return on Equity78
EBIT Margin65
Gross Profitability43
Cash Conversion40
Accruals13
Owner Earnings Margin47
Sales growth53
Profit Growth59
Long-Term EPS Growth55
Owner Earnings Growth87
Reinvestment11
Price momentum30
Debt load45
Refinancing92
Debt Payback20
Liquidity83
Analyst ratings57
Opinion Changes86
Price Target Upside81
Market mood84
Value Creation16/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Siegfried generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountrySwitzerland
IndustryLife Sciences Tools & Services
SizeMedium
TypePublic Company
ExchangeSWX
Employees1,722
ISINCH1429326825
Last UpdateApr 2, 2026
Themes
OphthalmologyAddictionPain ManagementGeneticsRespiratoryCentral Nervous SystemBiotechnologyHealth CareMedicalPharmaceutical

Description

Siegfried Holding AG (Siegfried) specializes in the development and manufacture of active pharmaceutical ingredients (APIs) and drug products for the pharmaceutical and biotechnology industries. The company serves a diverse range of customers, includ…

Analysis

Middle-of-the-road

Siegfried Holding AG is a middle-of-the-road business: neither the economics nor the price stand out from the peer group. One caution: reported profits have recently run ahead of actual cash, which we track closely.

The price is expensive. You pay 79.4× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone. At today's price, the market is assuming roughly 25% yearly growth; analysts expect 11%. The market is pricing in far more than analysts expect: heroic expectations.

The trajectory is moderate and the balance sheet is adequate. The company scores 16/20 on our value-creation score: strong value creator. Analysts lean positive.

What to watch: Some accounting patterns deserve a closer look. Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
96
2023202420252026

All-time high

96

Jun 2026

All-time low

47

Jan 2024

Average rank

77

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
58
41
51
60
Price/Earnings
24
32
37
32
Price/Book
51
32
33
36
Dividend Yield
55
45
32
34
Value (overall)
60
39
34
35

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Siegfried with its peers
Merck (DE)
GER:MRK
12
CountryGermany
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →
Compugen
NAQ:CGEN
19
CountryIsrael
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Bachem
SWX:BANB
59
CountrySwitzerland
IndustryLife Sciences Tools & Services
SizeMedium
Full Stock Analysis →
Recordati
MIL:REC
54
CountryItaly
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Heidelberg Pharma
GER:HPHA
32
CountryGermany
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Evotec
GER:EVT
17
CountryGermany
IndustryLife Sciences Tools & Services
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →